Galton DJ. Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis. Curr Opin Lipidol. 2017;28(4):308–12. https://doi.org/10.1097/MOL.0000000000000425.

Article  CAS  PubMed  Google Scholar 

Bornfeldt KE. Apolipoprotein C3: form begets function. J Lipid Res. 2024;65(1):100475. https://doi.org/10.1016/j.jlr.2023.100475.

Article  CAS  PubMed  Google Scholar 

Gagnon E, Arsenault BJ. Drug target mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention. Atherosclerosis. 2024;391:117501. https://doi.org/10.1016/j.atherosclerosis.2024.117501.

Article  CAS  PubMed  Google Scholar 

Patel RS, Pasea L, Soran H, Downie P, Jones R, Hingorani AD, et al. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. Cardiovasc Diabetol. 2022;21(1):102. https://doi.org/10.1186/s12933-022-01525-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiss L, Fűr G, Mátrai P, Hegyi P, Ivány E, Cazacu IM, et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci Rep. 2018;8(1):14096. https://doi.org/10.1038/s41598-018-32337-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80–5. https://doi.org/10.1016/j.tcm.2019.03.001.

Article  PubMed  Google Scholar 

Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170(9):626–34. https://doi.org/10.7326/M19-0203.

Article  PubMed  Google Scholar 

Tomlinson B, Wu QY, Zhong YM, Li YH. Advances in Dyslipidaemia treatments: focusing on ApoC3 and ANGPTL3 inhibitors. J Lipid Atheroscler. 2024;13:2–20. https://doi.org/10.12997/jla.2024.13.1.2.

Article  CAS  PubMed  Google Scholar 

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438–47. https://doi.org/10.1056/NEJMoa1400283.

Article  CAS  PubMed  Google Scholar 

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by Volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408–15. https://doi.org/10.2337/dc16-0126.

Article  CAS  PubMed  Google Scholar 

Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531–42. https://doi.org/10.1056/NEJMoa1715944.

Article  CAS  PubMed  Google Scholar 

Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264–75. https://doi.org/10.1016/S2213-8587(21)00046-2.

Article  CAS  PubMed  Google Scholar 

Oral EA, Garg A, Tami J, Huang EA, O’Dea LStL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN Study. J Clin Lipidol. 2022;16:833–49. https://doi.org/10.1016/j.jacl.2022.08.008.

Article  PubMed  Google Scholar 

Tardif JC, Karwatowska-Prokopczuk E, St Amour E, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401–12. https://doi.org/10.1093/eurheartj/ehab820.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for Hypertriglyceridemia in patients at High Cardiovascular Risk. N Engl J Med. 2024 Apr;7. https://doi.org/10.1056/NEJMoa2402309.

Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial. JAMA Cardiol 2024 Apr 7:e240959. https://doi.org/10.1001/jamacardio.2024.0959.

Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, Acute Pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024 Apr;7. https://doi.org/10.1056/NEJMoa2400201.

Cheng Y, Li T, Tan P, Du Y, Huang Z, Shi H, et al. Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. Endocrine. 2022;76:253–62. https://doi.org/10.1007/s12020-022-03025-8.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hofmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n7.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(l4898). https://doi.org/10.1136/bmj.l4898.

Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Soft. 2010;36:1–48. https://doi.org/10.18637/jss.v036.i03.

Article  Google Scholar 

Ramms B, Gordts PLSM. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opi Lipidol. 2018;29(3):171–9. https://doi.org/10.1097/MOL.0000000000000502.

Article  CAS  Google Scholar 

Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep. 2021;23(5):20. https://doi.org/10.1007/s11883-021-00914-7.

Article  CAS  PubMed  Google Scholar 

Dallinga-Thie GM, Berk-Planken IIL, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C–III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27(6):1358–64. https://doi.org/10.2337/diacare.27.6.1358.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Simental-Mendía LE, Katsiki N, Reiner Ž, Banach M, Pirro M, et al. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;8(11):e021508. https://doi.org/10.1136/bmjopen-2018-021508.

Article  PubMed  Google Scholar 

Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. https://doi.org/10.1186/s12944-017-0541-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024;31(2):70–7. https://doi.org/10.1097/MED.0000000000000857.

Article  CAS  PubMed  Google Scholar 

Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials. Eur J Clin Invest. 2022;52(11):e13841. https://doi.org/10.1111/eci.13841.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023;17:342–55. https://doi.org/10.1016/j.jacl.2023.03.007.

Article  PubMed  Google Scholar 

Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep. 2023;25(10):701–9. https://doi.org/10.1007/s11883-023-01140-z.

Article  PubMed  PubMed Central  Google Scholar